Meet our SPARK Fellows
Introducing Cohort 8
Eduardo Davila, PhD
Tumor Infiltrating Lymphocyte Therapy Switch
Email Address:EDUARDO.DAVILA@CUANSCHUTZ.EDU
Tumor Infiltrating Lymphocyte Therapy Switch
The objective of this study is to validate and optimize the use of a synthetic receptor that can selectively expand and differentiate immune cells "on-demand" in cancer patients undergoing cellular therapies. Current treatments involving chemotherapies for preconditioning result in the transient depletion of endogenous T cells and other important immune cells, leading to toxicities and complications. The researchers have developed a synthetic protein that induces T cell proliferation in tissue culture when cross-linked with FDA-approved anti-Her2 antibodies. The study aims to identify the optimal treatment regimen for promoting the proliferation of engineered cells in an in vivo preclinical mouse setting and assess their antitumor activity. Success in this research could lead to significant advancements in cellular therapy, benefiting other treatment areas such as stem cell therapy, infectious diseases, and autoimmunity.
Learn more about Dr. DavilaCohort 7
Cohort 6
Eduardo Davila, PhD
Tumor Infiltrating Lymphocyte Therapy Switch
Email Address:EDUARDO.DAVILA@CUANSCHUTZ.EDU
Tumor Infiltrating Lymphocyte Therapy Switch
The objective of this study is to validate and optimize the use of a synthetic receptor that can selectively expand and differentiate immune cells "on-demand" in cancer patients undergoing cellular therapies. Current treatments involving chemotherapies for preconditioning result in the transient depletion of endogenous T cells and other important immune cells, leading to toxicities and complications. The researchers have developed a synthetic protein that induces T cell proliferation in tissue culture when cross-linked with FDA-approved anti-Her2 antibodies. The study aims to identify the optimal treatment regimen for promoting the proliferation of engineered cells in an in vivo preclinical mouse setting and assess their antitumor activity. Success in this research could lead to significant advancements in cellular therapy, benefiting other treatment areas such as stem cell therapy, infectious diseases, and autoimmunity.
Learn more about Dr. DavilaCohort 5
Eduardo Davila, PhD
Tumor Infiltrating Lymphocyte Therapy Switch
Email Address:EDUARDO.DAVILA@CUANSCHUTZ.EDU
Tumor Infiltrating Lymphocyte Therapy Switch
The objective of this study is to validate and optimize the use of a synthetic receptor that can selectively expand and differentiate immune cells "on-demand" in cancer patients undergoing cellular therapies. Current treatments involving chemotherapies for preconditioning result in the transient depletion of endogenous T cells and other important immune cells, leading to toxicities and complications. The researchers have developed a synthetic protein that induces T cell proliferation in tissue culture when cross-linked with FDA-approved anti-Her2 antibodies. The study aims to identify the optimal treatment regimen for promoting the proliferation of engineered cells in an in vivo preclinical mouse setting and assess their antitumor activity. Success in this research could lead to significant advancements in cellular therapy, benefiting other treatment areas such as stem cell therapy, infectious diseases, and autoimmunity.
Learn more about Dr. Davila